This decade will bring major changes to the therapy of diabetes. New d
rugs are likely to include monomeric insulins, fatty-acid-oxidation in
hibitors, insulin-secretion inducers, and nutrition modifiers. Likely
new devices include improved insulin pens, less invasive methods of in
sulin administration, and noninvasive blood glucose monitoring. The us
e of computers will integrate this care, and artificial intelligence w
ill provide new approaches to all of health care. An integrated system
for using these new technologies, such as staged diabetes management,
will ensure an orderly, cost-effective transition in therapy by the e
ntire health-care community.